DekaBank Deutsche Girozentrale Has $14.80 Million Position in Bruker Co. (NASDAQ:BRKR)

DekaBank Deutsche Girozentrale cut its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 24.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 231,820 shares of the medical research company’s stock after selling 75,220 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.16% of Bruker worth $14,799,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. TD Asset Management Inc increased its holdings in shares of Bruker by 7.4% during the 1st quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock worth $168,036,000 after acquiring an additional 123,984 shares during the last quarter. Congress Asset Management Co. MA increased its holdings in shares of Bruker by 3.5% during the 1st quarter. Congress Asset Management Co. MA now owns 1,414,362 shares of the medical research company’s stock worth $132,865,000 after acquiring an additional 47,301 shares during the last quarter. Norges Bank acquired a new position in shares of Bruker during the 4th quarter worth approximately $74,582,000. Bank of New York Mellon Corp increased its holdings in shares of Bruker by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 966,069 shares of the medical research company’s stock worth $61,645,000 after acquiring an additional 27,870 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Bruker by 3.5% during the 1st quarter. Janus Henderson Group PLC now owns 869,205 shares of the medical research company’s stock worth $81,648,000 after acquiring an additional 29,566 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of BRKR stock opened at $65.66 on Monday. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker Co. has a twelve month low of $53.79 and a twelve month high of $94.86. The company has a market cap of $9.94 billion, a P/E ratio of 23.88, a P/E/G ratio of 2.31 and a beta of 1.18. The business has a fifty day simple moving average of $64.17 and a 200 day simple moving average of $73.43.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. During the same period in the prior year, the company earned $0.50 EPS. Bruker’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, sell-side analysts forecast that Bruker Co. will post 2.61 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Monday, September 2nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.30%. Bruker’s dividend payout ratio is currently 7.27%.

Analyst Ratings Changes

A number of research analysts have commented on BRKR shares. Stifel Nicolaus decreased their price objective on Bruker from $81.00 to $77.00 and set a “hold” rating on the stock in a report on Monday, May 20th. The Goldman Sachs Group decreased their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Jefferies Financial Group started coverage on Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price objective on the stock. Bank of America decreased their price objective on Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Monday, May 20th. Finally, Wells Fargo & Company initiated coverage on Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.40.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.